January 29, 2019 Rentschler Biopharma SE appoints Dr. Christian Hunzinger as Senior Vice President Project Management
Laupheim, January 29, 2019 - Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today the appointment of Dr. Christian Hunzinger (48) as the new Senior Vice President Project Management, effective from January 15, 2019. Dr. Hunzinger has over 15 years of industry experience in research and development of biopharmaceuticals. He succeeds Dr. Klaus Schoepe who held the same position and will retire in the course of 2019 after working for the company for 14 years.
“We are delighted to welcome Dr. Christian Hunzinger to Rentschler Biopharma. His professional expertise in production and development of biopharmaceutical products and his outstanding experience in the field of project management will significantly contribute to meeting the needs of our clients even better and more sustainably. Together with his project managers, he will intensify and reinforce strategic partnerships with our clients,” explained Dr. Frank Mathias, CEO of Rentschler Biopharma SE.
Dr. Hunzinger added: “Due to new technologies and, above all, increasing digitalization, the biopharmaceutical industry will change considerably in the coming years such that strategic consulting services and client focus will become even more important in project management. I am very much looking forward to actively shaping this change as part of the Rentschler Biopharma team and to develop highly innovative and tailored solutions for implementation and controlling of projects in close coordination with our clients. Our aim is to ensure high-quality development and production of biopharmaceuticals – depending on client requirements either for clinical testing or to meet the market and ultimately patients’ needs.”
Prior to joining Rentschler Biopharma, Dr. Hunzinger was Biotech CMC Program Lead at Merck where, within their strategic alliance with Pfizer, he was responsible for all issues relating to CMC development and thus substantially involved in the successful approval of the cancer immunotherapeutic drug Bavencio® (avelumab). During his time at Merck, he held various posts with increasing responsibility in the fields of Healthcare and Life Sciences, during which he acquired broad knowledge in research & development of biopharmaceutical products. He started his professional carrier as a research scientist at ProteoSys AG. Dr. Hunzinger received his diploma and PhD in biology at the Johannes Gutenberg-University in Mainz.
Rentschler Biopharma SE